{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:26:26Z","timestamp":1785331586424,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:00:00Z","timestamp":1640131200000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejso.2019.03.021","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T01:57:06Z","timestamp":1553047026000},"page":"139-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. A single center comparative study"],"prefix":"10.1016","volume":"47","author":[{"given":"Matthieu","family":"Siebert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alyami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Gallice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Laplace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Passot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoual","family":"Bakrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahan","family":"Kepenekian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2019.03.021_bib1","first-page":"18","article-title":"Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective","volume":"7","author":"Neuwirth","year":"2016","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.ejso.2019.03.021_bib2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/SLA.0b013e31827e9289","article-title":"Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?","volume":"257","author":"Go\u00e9r\u00e9","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2019.03.021_bib3","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1245\/s10434-015-5081-3","article-title":"Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility?","volume":"23","author":"Chia","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2019.03.021_bib4","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejso.2019.03.021_bib5","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejso.2019.03.021_bib6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"10.1016\/j.ejso.2019.03.021_bib7","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3748\/wjg.v24.i19.2130","article-title":"Pressurized intraperitoneal aerosol chemotheprapy after misdiagnosed gastric cancer: case report and review of the literature","volume":"21","author":"Nowacki","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejso.2019.03.021_bib8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/bjs.10521","article-title":"Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis","volume":"104","author":"Grass","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2019.03.021_bib9","first-page":"6852749","article-title":"Feasibility and safety of pressurized intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis: a retrospective cohort study","author":"H\u00fcbner","year":"2017","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.ejso.2019.03.021_bib10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12957-016-0892-7","article-title":"Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis","volume":"14","author":"Robella","year":"2016","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejso.2019.03.021_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis","volume":"20","author":"Nadiradze","year":"2016","journal-title":"J.\u00a0Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract"},{"key":"10.1016\/j.ejso.2019.03.021_bib12","first-page":"364","article-title":"Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis","volume":"18","author":"Demtr\u00f6der","year":"2016","journal-title":"Colorectal Dis. Off. J. Assoc. Coloproctology G. B. Irel."},{"key":"10.1016\/j.ejso.2019.03.021_bib13","first-page":"2178","article-title":"Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis","volume":"43","author":"Alyami","year":"2017","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"key":"10.1016\/j.ejso.2019.03.021_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12957-016-1008-0","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"14","author":"Girshally","year":"2016","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejso.2019.03.021_bib15","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1002\/cncr.25116","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis","volume":"116","author":"Franko","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2019.03.021_bib16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejso.2019.03.021_bib17","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1634\/theoncologist.2014-0032","article-title":"Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data","volume":"19","author":"Kirstein","year":"2014","journal-title":"Oncol"},{"key":"10.1016\/j.ejso.2019.03.021_bib18","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.3747\/co.24.3824","article-title":"Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline","volume":"24","author":"Francis","year":"2017","journal-title":"Curr. Oncol. Tor. Ont"},{"issue":"Suppl 3","key":"10.1016\/j.ejso.2019.03.021_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000088481","article-title":"Managing patients treated with bevacizumab combination therapy","volume":"69","author":"Gordon","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.ejso.2019.03.021_bib20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","article-title":"A\u00a0review on bevacizumab and surgical wound healing: an important warning to all surgeons","volume":"62","author":"Gordon","year":"2009","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.ejso.2019.03.021_bib21","first-page":"991","article-title":"Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study","volume":"44","author":"Nowacki","year":"2018","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"key":"10.1016\/j.ejso.2019.03.021_bib23","first-page":"597","article-title":"Quantitative prognostic indices in peritoneal carcinomatosis","volume":"32","author":"Gilly","year":"2006","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"key":"10.1016\/j.ejso.2019.03.021_bib24","volume":"vol. 79","year":"2009"},{"key":"10.1016\/j.ejso.2019.03.021_bib25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11605-017-3565-0","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedure for non-resectable peritoneal carcinomatosis (with video)","volume":"22","author":"Cazauran","year":"2018","journal-title":"J.\u00a0Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract"},{"key":"10.1016\/j.ejso.2019.03.021_bib26","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/SAP.0b013e31824e5e57","article-title":"Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon","volume":"71","author":"Sharma","year":"2013","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.ejso.2019.03.021_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.ejso.2019.03.021_bib28","series-title":"NCCN guidelines index table of contents","first-page":"180","author":"Benson","year":"2018"},{"key":"10.1016\/j.ejso.2019.03.021_bib29","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1245\/s10434-013-3442-3","article-title":"Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin","volume":"21","author":"Eveno","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2019.03.021_bib30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1245\/s10434-006-9074-0","article-title":"Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study","volume":"14","author":"D'Angelica","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2019.03.021_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jamcollsurg.2007.06.290","article-title":"Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases","volume":"206","author":"Reddy","year":"2008","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.ejso.2019.03.021_bib32","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/CAD.0b013e328349c7bb","article-title":"Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy","volume":"22","author":"Kriegel","year":"2011","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejso.2019.03.021_bib33","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jvir.2009.01.022","article-title":"Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy","volume":"20","author":"Zawacki","year":"2009","journal-title":"J.\u00a0Vasc. Interv. Radiol. JVIR"},{"key":"10.1016\/j.ejso.2019.03.021_bib34","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00404-018-4673-0","volume":"297","author":"Dueckelmann","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ejso.2019.03.021_bib35","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.3748\/wjg.v21.i16.5072","article-title":"Value of bevacizumab in treatment of colorectal cancer: a meta-analysis","volume":"21","author":"Qu","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejso.2019.03.021_bib36","first-page":"57","article-title":"Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review","volume":"7","author":"Aravantinos","year":"2014","journal-title":"J\u00a0Ovarian Res"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879831930349X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879831930349X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T16:07:47Z","timestamp":1755274067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074879831930349X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S074879831930349X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2019.03.021","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. A single center comparative study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2019.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}